Exclusive Summary

• The patent for the originator Valtrex has long expired, and Valacyclovir is a globally recognized first-line standard of care for herpes viruses, representing a massive and mature market demand.
• With over 4 billion people globally infected with HSV and rising shingles incidence due to aging populations, distributors are guaranteed a huge patient base and steady repeat purchases.
• Offering higher bioavailability and less frequent dosing than acyclovir, the 0.3g * 7 tablets packaging is perfectly tailored for short-course episodic treatment of recurrent herpes flare-ups, ensuring high compliance.
• Backed by China's mature API-to-finished-dosage manufacturing integration, this distribution project can provide overseas partners with significant cost optimization and highly competitive profit margins.